Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.


Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening, chronic disease that can affect patients of all ages. aHUS is caused by uncontrolled complement activation due to genetic defects of complement regulation. Plasma exchange or infusion has been used to manage aHUS and may transiently maintain hematologic variables in some patients, but as the underlying complement dysregulation persists, end-stage renal disease or death occurs in 33% to 40% of patients during the first clinical manifestation. Here we present a pediatric case showing that first-line eculizumab treatment successfully blocked the progression of thrombotic microangiopathy in aHUS.

DOI: 10.1542/peds.2013-1787

1 Figure or Table

Citations per Year

1,088 Citations

Semantic Scholar estimates that this publication has 1,088 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Christmann2014EculizumabAF, title={Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.}, author={Martin Christmann and Matthias Hansen and Carsten Bergmann and Dirk Schwabe and Joerg Brand and Wilfried Schneider}, journal={Pediatrics}, year={2014}, volume={133 6}, pages={e1759-63} }